Boc-Ser-NHCH2C6H5 | 141108-78-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-Ser-NHCH2C6H5
• 英文别名: tert-butyl (S)-(1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl)carbamate；N-tert-Butyloxycarbonyl-L-serine benzylamide；Tert-butyl N-[(1S)-1-(benzylcarbamoyl)-2-hydroxyethyl]carbamate；tert-butyl N-[(2S)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate
• CAS: 141108-78-3
• 化学式: C₁₅H₂₂N₂O₄
• 分子量: 294.351
• InChiKey: CTFYHNRRPGOYJS-LBPRGKRZSA-N

物化性质

• 沸点：
  532.9±50.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  Boc-Ser-NHCH2C6H5 在 sodium periodate 、 sodium hydroxide 作用下， 以 aq. phosphate buffer 、 二氯甲烷 、 乙腈 为溶剂， 反应 1.5h， 生成 N-benzyl-2-oxoacetamide
  参考文献：
  名称：

  噻唑烷-5-亚胺的形成作为无催化剂的蛋白质和活细胞标记生物正交反应

  摘要：

  开发了一种先前未描述的涉及形成噻唑烷-5-亚胺键的反应以进行生物缀合。这种简单的缩合反应具有很高的特异性，可以在水性介质中操作，因此可以在生理条件下化学选择标记肽，蛋白质和活细胞，而无需使用有毒的催化剂或还原剂。

  DOI：

  10.1021/acs.orglett.8b03195
• 作为产物：
  描述：

  BOC-L-丝氨酸 在 N-甲基吗啉 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 Boc-Ser-NHCH2C6H5
  参考文献：
  名称：

  Naqvi, T.; Dhawan, V. C.; Haq, W., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1994, vol. 33, # 5, p. 445 - 450

  摘要：

  DOI：

文献信息

• DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS
  申请人：Seikagaku Corporation

  公开号：US20170001948A1

  公开（公告）日：2017-01-05

  The invention provides a diamine crosslinking agent for acidic polysaccharides consisting of a diamine compound having a primary amino group at both terminals and an ester or thioester bond in the molecule, wherein the number of atom in the linear chain between at least one of the amino groups and the carbonyl carbon in the ester or thioester is 1 to 5; in particular, a diamine crosslinking agent for acidic polysaccharides which is represented by the general formula (I) below: [the symbols in the formula are as described in the specification]; a crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between the amino groups in the diamine crosslinking agent and carboxyl groups in an acidic polysaccharide; and a medical material including the crosslinked product.

  该发明提供了一种用于酸性多糖的二胺交联剂，其由一种二胺化合物组成，该化合物在分子中的两个末端具有主要氨基团，并且在至少一个氨基团与酯或硫酯中的羰基碳之间的线性链中的原子数为1至5；特别是一种用下面的通式(I)表示的酸性多糖的二胺交联剂： [式中的符号如说明书中所述]；通过在二胺交联剂的氨基团和酸性多糖中的羧基团之间形成酰胺键而获得的交联酸性多糖；以及包括所述交联产物的医用材料。
• Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound
  申请人：KANEBO LTD.

  公开号：EP0472826A2

  公开（公告）日：1992-03-04

  Novel quinolinecarboxylic acid derivatives of the formula: wherein Z is in which R¹ is hydrogen atom, a halogen atom, hydroxy or a lower alkyloxy; R² is a halogen atom, hydroxy or a lower alkyloxy; R³ is a lower alkyl; and R⁴ is hydroxy or a di(lower alkyl)amino, and a pharmaceutically acceptable salt thereof, which have excellent antibacterial activities and are useful as an antibacterial agent, a pharmaceutical composition containing the same, and process for preparing the same. This invention relates also to the intermediate compound used for preparing the novel quinolinecarboxylic acid derivative.

  式中的新型喹啉羧酸衍生物： 其中 Z 是 其中 R¹ 是氢原子、卤素原子、羟基或低级烷氧基；R² 是卤素原子、羟基或低级烷氧基；R³ 是低级烷基；R⁴ 是羟基或二(低级烷基)氨基，及其药学上可接受的盐；这些衍生物具有优异的抗菌活性，可用作抗菌剂，含有这些衍生物的药物组合物，以及制备这些衍生物的工艺。本发明还涉及用于制备新型喹啉羧酸衍生物的中间体化合物。
• Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials
  申请人：Seikagaku Corporation

  公开号：US10919840B2

  公开（公告）日：2021-02-16

  The invention provides a diamine crosslinking agent for acidic polysaccharides consisting of a diamine compound having a primary amino group at both terminals and an ester or thioester bond in the molecule, wherein the number of atom in the linear chain between at least one of the amino groups and the carbonyl carbon in the ester or thioester is 1 to 5; in particular, a diamine crosslinking agent for acidic polysaccharides which is represented by the general formula (I) below: [the symbols in the formula are as described in the specification]; a crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between the amino groups in the diamine crosslinking agent and carboxyl groups in an acidic polysaccharide; and a medical material including the crosslinked product.

  本发明提供了一种用于酸性多糖的二胺交联剂，该交联剂由二胺化合物组成，该二胺化合物的两个末端均有伯氨基，分子中具有酯键或硫酯键，其中至少一个氨基与酯键或硫酯键中的羰基碳之间的线性链上的原子数为 1 至 5；特别是一种用于酸性多糖的二胺交联剂，该交联剂由以下通式（I）表示： [式中符号如说明书所述]；通过二胺交联剂中的氨基与酸性多糖中的羧基之间的酰胺键形成交联而获得的交联酸性多糖；以及包括交联产物的医用材料。
• （1R，2S，5S）-6，6-二甲基-3-氮杂双环[3，1，0]己基-2-羧酸酯的制备方法
  申请人：浙江新和成股份有限公司

  公开号：CN115028570A

  公开（公告）日：2022-09-09

  本发明涉及一种(1R，2S，5S)‑6，6‑二甲基‑3‑氮杂双环[3，1，0]己基‑2‑羧酸酯的制备方法，所述制备方法以N保护的L‑丝氨酸作为起始原料，通过胺化反应、氧化反应、wittig反应、加成反应、还原反应、环合反应、脱保护以及酯化反应，得到(1R，2S，5S)‑6，6‑二甲基‑3‑氮杂双环[3，1，0]己基‑2‑羧酸酯，避免使用酶催化、手性拆分等步骤，反应灵活，收率高，成本低，且降低了工业废水、废盐的产生，有利于工业化大规模生产和下游产品的制备，可以满足终端药物生产的巨大需求。
• Development of Dual-Acting Agents for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition. 3. Synthesis and Biological Activities of Oxazolecarboxamide-Substituted ω-Phenyl-ω-(3-pyridyl)alkenoic Acid Derivatives and Related Compounds
  作者：Kumiko Takeuchi、Todd J. Kohn、Timothy A. True、Dale E. Mais、James H. Wikel、Barbara G. Utterback、Virginia L. Wyss、Joseph A. Jakubowski

  DOI：10.1021/jm980173n

  日期：1998.12.1

  A novel series of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA(2) receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid (14) with K-d = 9.9 +/- 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 +/- 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, "shunt" effect to elevate PGI(2) level, and absence of agonist activity.